Skip to main content
Explore URMC

UR Medicine

menu
UR Medicine / Primary Care / Primary Care Practices / Complex Care Center / For Providers / Sickle Cell Disease CME & Educational Materials
 

Sickle Cell Disease CME & Educational Materials

Supporting Complex Care: Sickle Cell

Follow the link in the yellow box below to the URMC Center for Experiential Learning (CEL) website to view this educational presentation. There is no fee to simply view the presentation.**

CME Online Module Supporting Complex Care: Sickle Cell

** Please note – In order to receive CME credit for this educational series, please select “Click Here to Register” from the options on the CEL website and follow the instructions for payment.

The goal of this series of online modules (total time: 2.5 hours) about Sickle Cell Disease is to give providers a broad understanding of evidence-based diagnosis and management of acute complications of the disease. Topics will include:

  • evidence-based management of acute “pain” (vaso-occlusive crisis, acute chest)
  • health system impact of disease management
  • patient-focused impact of disease
  • resources and programs in the Greater Rochester area that can be accessed directly or translated into other regional settings

Accreditation
The University of Rochester School of Medicine & Dentistry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Certification
The University of Rochester School of Medicine and Dentistry designates this enduring material for a maximum of 2.50 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

What Health Care Providers Need to Know About Caring for Adult Patients with Sickle Cell Disease

Being Sickle Cell Smart

  • This one page flyer explain sickle cell disease and how health care providers and treatment can help.

Being Sickle Cell Smart one-page flyer

Hydroxurea

  • works by helping the body produce more HgF, or fetal hemoglobin, and produce less HgS, or sickled hemoglobin
  • was approved by the US Food and Drug Administration (FDA) and has been used to treat sickle cell disease for over 25 years
  • is proven to reduce pain and long-term complications when taken regularly

Hydroxyurea Educational Brochure

Acute Chest Syndrome

  • is a life-threatening complication of sickle cell disease causes chest pain, fever and difficulty breathing
  • can be caused by a lung infection or by sickle cells blocking blood vessels in your lungs
  • may require emergency medical treatment with antibiotics and other treatments